The ID Pipeline: FDA Activity From the Week of December 15, 2019

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of December 15, 2019.

Ebola Vaccine Approved by FDA

The FDA has announced that the Ebola vaccine Ervebo has been approved for administration in individuals 18 years of age and older. This is the first vaccine for the prevention of Ebola virus disease that has been authorized in the United States. The approval was granted to Merck & Co., Inc.

Ervebo is administered as a single-dose injection and is a live, attenuated vaccine.

The vaccine was used as an investigational vaccine in the Democratic Republic of the Congo where the second largest Ebola outbreak is ongoing. The vaccine was authorized by the World Health Organization under an expanded access program to help mitigate the outbreak.

Read the full article here.

FDA Clears Investigational New Drug Application for DARE-BV1 for Bacterial Vaginosis to Commence Phase 3 Clinical Study

Daré Bioscience announced that the FDA has cleared its investigational new drug application for DARE-BV1, a novel thermosetting bioadhesive hydrogel containing 2% clindamycin phosphate. DARE-BV1 is being developed for vaginal administration for the treatment of bacterial vaginosis, which affects more than 20 million women in the US.

The company is now cleared to commence the planned Phase 3 clinical study of DARE-BV1 in approximately 220 women to support a new drug application.

Read the press release